Trends and determining factors associated with adherence to antiretroviral therapy (ART) in Cameroon: a systematic review and analysis of the CAMPS trial by Lawrence Mbuagbaw et al.
Mbuagbaw et al. AIDS Research and Therapy 2012, 9:37
http://www.aidsrestherapy.com/content/9/1/37RESEARCH Open AccessTrends and determining factors associated with
adherence to antiretroviral therapy (ART) in
Cameroon: a systematic review and analysis of
the CAMPS trial
Lawrence Mbuagbaw1,2*, Lehana Thabane2,3, Pierre Ongolo-Zogo1, David Yondo1, Stephen Noorduyn2,
Marek Smieja2,4 and Lisa Dolovich5Abstract
Background: The benefits of antiretroviral therapy (ART) cannot be experienced if they are not taken as prescribed.
Yet, not all causes of non-adherence are dependent on the patient. Having to pay for medication reduces
adherence rates. Non- adherence has severe public health implications which must be addressed locally and
globally. This paper seeks to describe the trends in adherence rates reported in Cameroon and to investigate the
determinants of adherence to ART in the Cameroon Mobile Phone SMS (CAMPS) trial.
Methods: We conducted a systematic review of electronic databases (PubMed, Google Scholar, Web of Science,
CINAHL, EMBASE and PSYCINFO) for publications on adherence to ART in Cameroon (from January 1999 to May
2012) and described the trend in reported adherence rates and the factors associated with adherence. Data were
extracted in duplicate. We used multivariable analyses on the baseline data for 200 participants in the CAMPS trial
to determine the factors associated with adherence in four models using different measures of adherence (more
than 90% or 95% on the visual analogue scale, no missed doses and a composite measure: 100% on the visual
analogue scale, no missed doses and all pills taken on time).
Results: We identified nine studies meeting our inclusion criteria. Adherence to ART in Cameroon has risen steadily
between 2000 and 2010, corresponding to reductions in the cost of medication. The factors associated with
adherence to ART in Cameroon are grouped into patient, medication and disease related factors. We also identified
factors related to the health system and the patient-provider relationship. In the CAMPS trial, education, side effects
experienced and number of reminder methods were found to improve adherence, but only using multiple
reminder methods was associated with better adherence in all the regression models (Adjusted Odds Ratio [AOR]
4.11, 95% Confidence Interval [CI] 1.89, 8.93; p<0.001; model IV).
Conclusions: Reducing the cost of ART is an important aspect of ensuring adequate adherence rates. Using
multiple reminder methods may have a cumulative effect on adherence to ART, but should be investigated further.
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The advent of antiretroviral medication as a treatment for
HIV is one of the most celebrated advances in medicine
[1]. Antiretroviral therapy (ART) reduces viral loads to
undetectable levels, and dramatically decreases morbidity
and mortality. Decreasing serum viral load with antiretro-
viral medication also reduces mother to child transmission
rates [2,3]. However, viral replication still occurs in reser-
voirs like lymph node or gastrointestinal T-cells even
when viral loads are undetectable [4,5]. As such, good
adherence is necessary to maintain prolonged viral sup-
pression [5]. Non-adherence to HIV medication is a major
reason for treatment failure, the development of resistant
strains, and increased costs [6]. It is also one of the key
predictors or determinants of success in the management
of HIV/AIDS and the progression to AIDS and death [7,8].
Non-adherence reduces the immunologic potential of ART
and is associated with drops in CD4-positive-T-lymphocyte
counts [9-11]. Non-adherence has also been found to be
associated with increased hospitalisations and longer
hospital stays [10,12]. Initial worries in the scientific com-
munity about non-adherence in sub-Saharan Africa were
dispelled when research findings demonstrated similar or
higher rates of adherence than in the developed world
[13]. However, only a third of people living with HIV
(PLHIV) take their medication as prescribed [1]. Non-
adherence leads to increased viremia which might lead to
increased transmissibility and consequently a higher inci-
dence of HIV. High risk activity may also lead to the
transmission of resistant strains to newly infected indivi-
duals, thereby reducing their therapeutic options [14,15].
Adherence to ART has clinical and public health implica-
tions, and should therefore be addressed on global and
local levels.
Defining adherence
Adherence can be narrowly defined as the “extent to which
patients take medications as prescribed by their health care
providers” [16], or more broadly as the “the extent to which
a person’s behaviour—taking medication, following a diet,
or executing lifestyle changes, corresponds with agreed
recommendations from a health care provider” [1]. The
former definition refers to compliance with medication as
prescribed by the provider while the latter goes beyond
medication to include all the recommendations jointly
agreed upon by both provider and client to improve health
care. The latter definition also highlights or acknowledges
additional factors such as diet or lifestyle which may affect
adherence. It also recognises that the client may not agree
with the recommendations of the health care provider.
Such factors are even more relevant in HIV where dietary
restrictions are required for the uptake of certain medica-
tions [17,18] and that certain lifestyles (e.g. substance
abuse) can lead to non- adherence to ART [19]. In thispaper, all degrees of adherence which are not optimal are
referred to as non-adherence.
The factors associated with adherence to ART exist in
many categories, defined in literature [1,16,19]:
Patient factors such as substance abuse, being male
(i.e. gender), depression, lower levels of education, lack of
self efficacy, extreme anxiety, extreme pain, no change in
health status despite ARTand non-white race are
significantly associated with non-adherence [1,19].
Medication factors like dose frequency, pill burden,
type of drug, inability to take medication when away
from home, food requirements, side effects are also
responsible for less than optimal adherence [1,19]. In
other words the complexity of the regimen and its side-
effects are associated with non-adherence.
Provider-related factors such as a poor patient-health
care provider relationship can affect the patient’s
overall satisfaction and trust in the provider. The
quality of these relationships is significantly associated
with better adherence [1,20,21].
Disease characteristics, notably stage and duration of
HIV infection, symptoms experienced and the presence
of opportunistic infections play a role in adherence to
ART. HIV related symptoms like nausea may impede a
patient from swallowing pills. Some studies report that
patients who have experienced an opportunistic
infection tend to be more adherent than those who
have not [1,22,23].
Clinical setting and health system factors may influence
use of services and adherence [19].
Adherence to ART in Cameroon
Cameroon has one of the highest rates of HIV in west
and central Africa, with 5.3% of the adult population
living with HIV. Of these, only 30% are receiving ART
[24]. Adherence to ART in Cameroon has changed over
the years for a multitude of reasons. Health system
changes like the decentralization of HIV treatment
centres and the subsidy of costs of medication and tes-
ting over the years have contributed to the variations in
the reported adherence rates. A substantial reduction in
costs occurred in 2004 [25] and ART has been provided
for free since 2007 [26]. As a result, the designs and the
contexts of the studies reporting rates of adherence to
ART in Cameroon also vary. The set of similar and
varying contextual factors in Cameroon make it a worth-
while case study to examine adherence to ART and learn
lessons that could be applied across the country. Ad-
herence rates in Cameroon have been measured using
patient reports, pharmacy refill data, attendance at
scheduled visits and blood testing [25-35]. These diffe-
rent methods have spawned adherence rates varying
from 10.1% to 97.5%, between 2000 and 2010. Faced
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data from a recent trial [36] to describe adherence to
ART and the associated determining factors. Adherence
rates are not only a predictor of treatment success, but
also an indication of how many resources should be
invested in adherence enhancement research and prac-
tice. This cannot be done without stable estimates for
adherence or a comprehensive list of locally relevant
determinants.
Additionally, in a changing world where new methods
and technologies arise to improve adherence rates, and
levels of stigma are declining, there may be a shift in
patients’ attitudes and practices related to adherence.
The objectives of this paper are:
 to review the literature on adherence in Cameroon
with specific emphasis on ART adherence rates and
its correlates or determinants, and
 to report the factors associated with adherence to
ART at baseline in the Cameroon Mobile Phone
SMS trial (CAMPS;36).
Methodology
Literature review of ART adherence rates in Cameroon
We searched electronic databases (PubMed, Google
Scholar, Web of Science, CINAHL, EMBASE and
PSYCINFO) for publications on adherence to ART in
Cameroon (from January 1999 to May 2012) using app-
ropriate combinations of keywords such as Cameroon,
Cameroun (French), adherence, compliance, antiretroviral
therapy, antiretroviral treatment and HIV. ART was in-
troduced in Cameroon in 1999 [37]. No language res-
trictions were set. Citations were screened and full text
obtained if they reported any measure of adherence to ART
in Cameroonian subjects. Completeness and adequacy of
reporting in the selected studies were assessed in duplicate
by noting their compliance to the 22-item Strengthening
the Reporting of Observational Studies in Epidemiology
(STROBE) checklist [38]. Data were also extracted in dupli-
cate: citation details; year study was conducted, city in
which study was conducted, adherence rate, method of
measure of adherence, study design, sample size and the
cost of ART at the time. Discrepancies were resolved by
discussion. We examined the evolution of adherence rates
taking into account the above characteristics. We also iden-
tified the reported factors associated with adherence and
classified them as patient variables, medication variables,
patient-provider relationship and health system characteris-
tics. These categories have previously been identified in
literature [16,19]. No statistical pooling was performed. The
factors associated with adherence were extracted only if
they resulted from multivariable analyses. The reported
odds ratios and p-values were used to confirm the associa-
tions reported.Adherence to ART in CAMPS
We conducted a cross-sectional analytical study based
on the baseline data for the Cameroon Mobile Phone
SMS (CAMPS) trial [36]. Data were collected from a
subset of patients (eligible for the trial) aged 21 or older,
who owned mobile phones and who agreed to take part
in the trial. The independent variables included socio-
demographics like age (in years), gender (male or
female), level of education (none and primary or second-
ary and university), disclosure of status to family mem-
bers (family aware or not aware of HIV status); clinical
features like presence or absence of an opportunistic in-
fection, Centers for Disease Control and Prevention
(CDC; [39]) classification (categorised as AIDS defining
condition or not), regimen (first line or second line),
duration on treatment (in months); the number of drug
side-effects experienced and the number of recall meth-
ods used. All the independent variables were those
reported in literature and collected for the CAMPS trial
[36]. The dependent variables were adherence measured
using a visual analogue scale (0–100), self report on the
number of missed doses and whether the doses were
taken on time in the week preceding the interview. We
also designed a composite measure of adherence based
on all three measures, which we dichotomized as adher-
ent (VAS=100; number of missed doses=0; all doses
taken on time=yes) and non-adherent (VAS<100; missed
doses >0; all doses taken on time=no).
We performed multivariable logistic regression with
adherence (dependent variable) dichotomized at the VAS
cut-offs of 90 and 95% (Model I and II). These cut-off
points represent the levels of adherence at which sus-
tained viral suppression can occur [5], and those often
used in literature [40,41]. We also analyzed the data
using the self reports of adherence as the dependent
variable, in which case one or more missed doses was
considered as non-adherence and no missed dose was
considered as good adherence (Model III). We repeated
these analyses using the composite measure of adhe-
rence (Model IV). The interaction between independent
variables was investigated based on associations reported
in the general literature and specifically for Cameroon.
Variables were introduced into the model in blocks
defined by the following categories: socio-demographic,
disease-related and medication-related. Model fit was
assessed using the Hosmer and Lemeshow goodness of
fit statistic [42].
Data were analysed using Predictive Analytic Software
(PASW) Version 17.0 (SPSS, Inc., 2009, Chicago, IL,
USA). Statistical significance was set at alpha= 0.05.
Adjusted odds ratios (AOR), 95% confidence intervals
(CI) and p-values are presented. The forest plot was
drawn using Stata Statistical Software (STATA) Release
12 (StataCorp LP, 2011, College Station, TX, USA).
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Literature review
We identified 9 studies conducted between 2000 and
2010 which reported adherence rates in Cameroon. The
mean number of reported items on the STROBE check-
list was 19.7 (standard deviation [SD] 1.38). Data from
the CAMPS trial was included in the analysis [36]. Five
of them were conducted in Yaoundé, the capital city of
Cameroon. The characteristics of these studies are
reported in Table 1. We observed an increasing trend in
adherence rates over time, which corresponds to the
reductions in cost of ART (Figure 1). Two studies were
outliers to this quasi-linear relationship. The first was
Kouanfack et al. [27], which reported high adherence
rates (88.7% and 97.5%, using biological markers and self
report respectively). This study was a drug trial and par-
ticipants received medication free of charge at a time
when medication costed 51.2 USD/month. The second,
Mosoko et al. [25], reported very low adherence rates
(10.1% using hospital records of the number of sche-
duled clinic visits attended). These data may be affected
by inaccuracies in hospital records (incompleteness was
handled using imputation techniques); participants who
lived far away were sometimes given medication for
more than one month; patients who lived in the nearby
city of Douala had other ART opportunities and this
measure (scheduled visits) considers all deaths and lost
to follow-up as non-adherent. Ideally, the cases of death
should be excluded from the denominator. The otherTable 1 Characteristics of studies reporting adherence to ART















2006 Yaoundé Cross-sectional (532)
Rougemont
et al.






Roux et al. 2006-2008 Yaoundé Prospective cohort (401)
Mahy et al. 2007-2008 Tokombere Cross-sectional (56)
Mbopi-Keou
et al.
2010 Dschang Cross-sectional (356)
CAMPS 2010 Yaoundé Cross-sectional (200)
*Costs vary per regimen, the highest costs are reported.
α Cross- sectional analysis of previously collected data without planning for needs o
β All methods in which all information used to measure adherence was obtained by
μ 50% was imputed to represent the trend graphically.study using attendance of scheduled visits [29] also
reported low adherence rates (<50%).
Determinants of, and factors associated with ART
adherence
In addition to the nine papers that reported adherence
rates, we identified two papers which reported on the
determinants of adherence to ART. These studies were
conducted in cross-national cohorts of patients from
Cameroon, the Democratic Republic of Congo and Burundi
(Table 2). These papers were provided additional informa-
tion on factors associated with adherence [34,35]. They
were not used in the trend analysis.
These factors were found to reduce adherence to ART:
binge drinking, drug use, tobacco use, lack of family sup-
port, experience of stigma, switching regimen, advanced
stage of disease, cost of care, distance from clinic, large
hospital size and no task shifting from physician to other
staff [25,28,30-35].
These factors increased adherence to ART: Female
gender, age greater than 49 years, higher levels of educa-
tion, positive perceptions of treatment, high motivation,
using reminder methods, satisfaction with information
provided by physician, higher CD4 count at initiation of
ART, and being transferred-in from another clinic
[30,31,33-35].
High monthly income [31,32] and increased duration
on medication [30,33,35] were both reported to either
increase or reduce adherence.in Cameroon
Adherence
rate
Method Cost of ART/month for that
year in USD*











56.6% Self Report β 12.8
64% (78%) Pharmacy data (Self
report)
12.8
53.9% Self report β 12.8
61-73% Self report β 12.8








90.5% Self report β 0
f an investigation.
interviewing the participant with either one question or a series of questions.
Figure 1 Trends in adherence rates to antiretroviral therapy and monthly cost of medication.
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the CAMPS Trial
In this sample of 200 adults, one fifth was older than
50 years, three-quarters were female, 98% had at least
primary education, and 90% reported that their families
were aware of their HIV status. The rest of their charac-
teristics are reported in Table 3. All the factors asso-
ciated with adherence that were collected in this data set
were used in the regression analysis. The baseline data
for participants in the CAMPS trial are reported in
Table 3.
In the first model, we dichotomized adherence using
the VAS at 95%. Using multiple recall methods was sig-
nificantly associated with adherence >95% (AOR 6.7,
95% CI 2.69, 16.56; p<0.001). In our second model,
adherence was dichotomized at 90%. Female gender was
associated with adherence >90% (AOR 0.28, 95% CI
0.09, 0.90; p=0.032), while secondary education (AOR,
4.4 95% CI 1.64, 11.92; p= 0.003) and multiple recall
methods (AOR, 7.89 95% CI 3.22, 19.33; p<0.001) were
associated with adherence >90%. In the third model we
used the number of missed doses as our measure of ad-
herence. Experiencing more side effects (AOR 2.25, 95%CI 1.13, 4.50; p= 0.021) and using multiple recall methods
increased the odds for not missing doses (AOR 7.28, 95%
CI 3.06, 17.32; p<0.001). In our last model we used a com-
posite measure of adherence that incorporated the VAS,
number of missed doses and timing of doses. Only the use
of multiple recall methods was associated with adherence
(AOR 4.11, 95% CI 1.89, 8.91; p<0.001). The Hosmer and
Lemeshow goodness-of-fit statistic for all the four models
had p-values greater than 0.05 implying a good fit [42].
These models are displayed in Figure 2.
Discussion
By reviewing the literature on adherence rates in
Cameroon, and analysing a new data set we have
produced an explanatory account of the trends in
adherence observed and the reported determinants.
We also identified another plausible means of en-
hancing adherence to ART: using multiple reminder
methods.
Despite the different study designs, locations and sam-
ple sizes there is a clear improvement in adherence rates
over time irrespective of how it is measured. This fin-
ding confirms and supports health policies that reduce
Table 2 Factors associated with adherence to ART in literature reports from Cameroon
Factors Reference (findings)
Patient variables
Female gender Rougemont et al. (↑)
Age>49 years Newman et al.* (↑); Freeman et al.**(↑)
High monthly income Rougemont et al. (↓); Boyer et al. ([28] ; ↑)
Education Freeman et al. (↑)*
Binge drinking Boyer et al. ([32] ; ↓); Roux et al. (↓); Newman et al.(↓)*
Drug use Freeman et al.(↓)*
Tobacco use Freeman et al.(↓)*
Lack of family support for adherence Boyer et al. ([32]; ↓);
Experiencing discrimination and stigma Boyer et al. ([32]; ↓);
Positive perception of treatment Roux et al. (↑)
Being transferred-in to HIV clinic Mbopi-Keou (↑)
Medication variables
Switching regimen Boyer et al. ([32]; ↓);
High motivation Roux et al.(↑)
Using a reminder method Roux et al.(↑)
Patient Provider Relationship
Satisfaction with information provided by physician Roux et al.(↑)
Disease characteristics
Advanced stage of disease Rougemont et al. (↓); Roux et al.(↑)
Increased duration on medication Roux et al.(↓); Freeman et al.(↑)*Mbopi-Keou (↑)
Higher CD4¥ count at initiation of ART β Mbopi-Keou (↑)
Health System/clinic Characteristics
Cost of care/Having to pay for care Mosoko et al.(↓), Boyer et al. ([32] ; ↓) ; Boyer et al. ([28] ; ↓) Laurent et al. (↓)
Increased distance from clinic Mosoko et al. (↓)
Large hospital size Boyer et al. ([32]; ↓);
No task shifting from physician to other staff Boyer et al. ([32]; ↓);
↓Reduces adherence; ↑increases adherence; * Cohort included participants from Cameroon, Burundi and the Democratic Republic of Congo; ** Cohort included
females from Cameroon, Burundi and the Democratic Republic of Congo; ¥ CD4-positive-T-lymphocyte; β Antiretroviral therapy.
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line with studies reporting that the main hindrances to ad-
herence in Africa are related to health system weaknesses
such as inadequate supply, human resource shortages and
poor infrastructure [29,32].
The determinants of adherence to ART identified in
the Cameroonian literature are a subset of factors identi-
fied elsewhere [19]. However, there are discrepancies as
to the role of monthly income and duration on ART on
adherence. Boyer et al. [32] reported better adherence
with a higher monthly income, while Rougemont et al.
[31] reported the contrary. Both studies were initiated in
the same period (2006) and therefore the cost of medi-
cation is unlikely to be the reason for this discrepancy.
On the other hand Boyer et al. conducted a multisite
(27 sites) study with a larger sample size (n=3151) com-
pared to Rougemont et al. (n=312) in a single site. The
results from Boyer et al. may be more plausible in theCameroonian context where, apart from free ART, other
related services are still funded by out-of-pocket payments
and having to pay for care has been identified as a cause
of non-adherence [25,28,29,32]. The larger sample is also
more likely to have more accurate and generalizable data,
especially since one of the sites included in Boyer et al. is
the same site where the Rougemont study was conducted.
Roux et al. [30] noted a drop in adherence rates with
increased duration on ART while Freeman et al. and
Mbopi-Keou et al. [33,35] noted the contrary. However,
these two samples differ greatly. Roux et al. describe a
multisite study in the Centre region of Cameroon, in 401
PLHIV over two years. Freeman et al. describe a cross-
national cohort of 8419 women from Cameroon, Burundi
and the Democratic Republic of Congo followed up for
two years. Female gender has been reported as a factor
for better adherence [31] and this discrepancy may
explain the interaction between gender and duration on
Table 3 Baseline characteristics of participants in the
CAMPS trial
Variable Statistic





Level of education: n (%)
None or primary 78 (39.0)
Secondary or university 122 (61.0)
Family aware of HIV status: n (%) 180 (90.0)
Presence of an opportunistic infection: n(%) 62 (31.0)




CDC* classification - AIDS defining illness§:n (%) 146 (73.0)
Regimen: n (%)δ
First line 179 (90.9)
Second line 18 (9.1)
Duration on ART (months): median (Q1, Q3) α 28.5 (9.0, 48.0)
CD4 (cells per mm3): median (Q1, Q3) 336.0 (200.5,487.7)
Adherence
Visual Analogue Scale: mean (SD) ε 90.5 (12.76)
Number of missed doses: mean (SD) μ 1.0 (0.00)
No missed doses: n (%) 127 (65.1)
Treatment taken on time: n (%) 108 (54.0)
Reasons for missing doses: n (%)
Forgot 54 (27.0)
Out of home 23 (11.5)
Out of tablets 7 (3.5)
Too busy 8 (4.0)
Side effects 2 (1.0)
Other reason 5 (2.5)








SD: standard deviation; BMI: body mass index; *Centres for Disease Control,
§ =CDC classifications: A3, B3, C1, C1, C3 [39]; α= 2missing; δ=3 missing; β=15
missing; ε= 10 missing ¥= 9missing; μ= 5 missing.
The reminder methods reported were: personal verbal reminders by
individuals, phone alarms, meal times, timing with TV shows and watches.
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might be the effect of continuous psycho-social sup-
port [33].
One study reported higher levels of adherence for
patients who initiated ART with high levels of CD4-posi-
tive-T-lymphocytes [33]. This finding is in favor of earlier
initiation of ART. Why patients who were transferred to
the clinic would have better adherence rates is unclear.
However, if they left their previous clinics due to service
provision issues or unsatisfactory interactions with clinic
staff, the latter clinic may provide a more favorable envi-
ronment for adherence.
Using multivariable analysis we identified gender, edu-
cation, side effects experienced, and number of reminder
methods as factors that affect adherence rates.
The male gender has often been reported as the most
likely to be non-adherent, maybe because males are
more likely to engage in other behaviours that influence
adherence such as binge drinking, tobacco use and drug
use [19]. This effect was not found in all models and is
not consistent across studies [19].
Level of education seems to play a role in adherence
behaviour. A significant difference in adherence exists
between people with secondary and those with no edu-
cation. Further increments in educational level show no
effect. This may imply that as concerns adherence to
ART there are no benefits to be gained from very high
levels of education. The benefits of education on adhe-
rence to ART can be obtained from secondary education.
This effect was not consistent across all models.
Our findings regarding side effects are contrary to
what is reported in literature. People who experienced
more side-effects were more likely to be adherent. No
other Cameroonian studies have identified side effects as
a determinant for adherence to ART. In the CAMPS
trial only 1% of those who missed doses reported side
effects to be the reason for not taking medication
(Table 3).
Only the number of reminder methods was associated
with adherence in all the models. Another Cameroonian
study reported the use of reminder methods to be asso-
ciated with better adherence [30]. This is the first study
to show that multiple reminders may have a cumulative
effect. A randomized clinical trial in Kenya found alarms
to have no effect on virological outcomes [43]. Simple
electronic alarms are not as complex as the reminder
methods described in this population (personal verbal
reminders by individuals, phone alarms, meal times,
timing with TV shows and watches). Other studies have
reported the use of mobile phone beeps and prayer times
by Muslims to remind them of when to take their medi-
cation [44]. The use of multiple and varied reminder
methods may address other causes of non-adherence like
forgetfulness and lack of social support.
Figure 2 Multivariable analysis using different measures of adherence.
Mbuagbaw et al. AIDS Research and Therapy 2012, 9:37 Page 8 of 10
http://www.aidsrestherapy.com/content/9/1/37
Mbuagbaw et al. AIDS Research and Therapy 2012, 9:37 Page 9 of 10
http://www.aidsrestherapy.com/content/9/1/37The difference in the four models suggests that the
factors associated with adherence depend somewhat on
how adherence is defined and the thresholds for acceptable
adherence. Different levels of adherence are associated with
different factors. It is unclear how this issue can be resolved
without a uniform and validated tool for measuring adhe-
rence rates in clinical practice or research, as all methods
have their advantages and flaws [16,45]. Self reported ad-
herence is by far the most popular method used, but how
it is used varies greatly [16,46]. On the one hand, a simple
visual analogue scale can be used to situate a patient’s
adherence; and on the other a series of questions related
to number of pills, timing, missed doses and identification
of pills, all fall under the canopy of self report.
In low resource settings, self report, attendance-based
and dispensing-based adherence measuring methods can
predict important clinical outcomes [46] and should be
collected routinely. Some measure of drug availability or
the occurrence of drug stock-outs should be documented
to explain trends in adherence behaviours.
Both sections of this paper may have limitations. Even
though we observed an increasing trend in adherence as
the cost of ART reduces, other temporal factors may con-
tribute to this trend, notably health system improvements
over the years and reductions in stigma and discrimi-
nation. These factors are reported as potential threats to
optimal adherence and are very likely to change over time.
The availability and use of reminder methods like mobile
phones may also enhance adherence over time [25,32].
Participants in this study (CAMPS) may not adequately
represent all the people living with HIV, but a subgroup
who are already on ART, and who own mobile phones.
Even though mobile phone ownership is widespread in
Cameroon, those who own them may differ significantly
from those who don’t.
Conclusions
A prerequisite to optimal adherence is the availability of
free or cheap medication. Irrespective of how it is mea-
sured, adherence rates tend to improve as the cost of medi-
cation is reduced. Improved financing mechanisms for
ART are an important way of ensuring adequate adherence
and improving outcomes for people living with HIV.
Multiple and varied reminder methods are more likely to
improve adherence than any single method alone. Further
research is required to elucidate what combinations of
reminder methods can produce the most desirable effects.
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